← FDA DRUG APPROVALS

FDA ANDA · ANDA211007

HEPARIN SODIUM

Sponsor: EMERGE BIOSCIENCE

APPLICATION
ANDA211007
TYPE
ANDA
ORIGINAL APPROVAL
2019-05-28
LATEST ACTION
2025-05-27
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HEPARIN SODIUMPrescription
HEPARIN SODIUM 10,000 UNITS/ML · INJECTABLE · INJECTION
HEPARIN SODIUMPrescription
HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE · INJECTION
HEPARIN SODIUMPrescription
HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE · INJECTION

Approval history

2025-05-27Labeling · Supplement 14 · standardAP
2025-05-27Labeling · Supplement 10 · standardAP
2019-05-28UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →